Barron’s: new drugs could help industry sales, shares

NEW YORK, Jan 31 (BestGrowthStock) – New drugs like Amgen Inc’s
(AMGN.O: ) osteoporosis injection Prolia could win regulatory
approval this year, helping the industry’s sales as well as
share prices, financial weekly Barron’s said.

Barron’s, in its Feb. 1 edition, listed prostate cancer
drug Provenge by Dendreon Corp (DNDN.O: ) and blood thinner
Xarelto, which Johnson & Johnson (JNJ.N: ) and Bayer (BAYGn.DE: )
plan to jointly market, as possible drugs that could be
approved by the U.S. Food and Drug Administration this year.

It also cited Jefferies & Co’s estimate that sales of
Qnexa, the obesity treatment developed by Vivus Inc (VVUS.O: ),
could reach $1.16 billion by 2015 if it wins FDA approval.

The report noted a jump in Novo Nordisk (NOVOb.CO: ) shares
after its injectable diabetes drug Victoza received FDA
approval last Monday.

Stock Market Money

(Editing by Martin Golan)

Barron’s: new drugs could help industry sales, shares